Prof Andrew Spencer
Prof Andrew Spencer is the Head of Malignant Haematology, Transplantation and Cellular Therapies Service and Head of Myeloma Research
Professor Andrew Spencer is Head of the Malignant Haematology, Transplantation and Cellular Therapies Service at The Alfred Hospital, Professor of Haematology at Monash University and Head of the Myeloma Research Group, all in Melbourne, Australia. Professor Spencer undertook his medical training in clinical and laboratory hematology at the Princess Alexandra Hospital, Brisbane, and the Royal Prince Alfred Hospital, Sydney.
He was then awarded a LRF (UK) Fellowship and spent 3 years at The Royal Postgraduate Medical School, London, United Kingdom where he undertook research into B-cell clonality in chronic myeloid leukemia and was awarded a Doctorate in Medicine from the University of London.
Andrew moved The Alfred Hospital in 1999, was appointed Head of Malignant Haematology and Stem Cell Transplantation Service in 2007 and established an early phase haematology clinical trials unit in 2009, with currently over 140 blood cancer trials open and >800 registered trial patients. He has >260 peer reviewed publications with over 22,000 citations and holds 5 international patents in multiple myeloma therapeutics.
Since 2015 he has been an invited speaker at 50 international meetings on genomics, therapeutics and disease monitoring in multiple myeloma and is an invited investigator of the International Myeloma Foundation (IMF) Black Swan Research Initiative. He serves on the scientific advisory boards of the IMF and the International Myeloma Working Group.
He Chairs the Myeloma and Related Diseases Registry (MRDR), the APAC MRDR and the associated M1000 liquid biopsy biobank. He established the Australasian Myeloma Research Consortium (AMaRC) in 2016.
Link to Publications:
https://research.monash.edu/en/persons/andrew-spencer